Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin Type A for Crow's Feet Lines
NCT01189747Phase 3Completed
- Sponsor
- Allergan
- Start
- Oct 2010
- Primary completion
- Apr 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in Crow's feet comparing onabotulinumtoxinA with Placebo (2 arms). Primary endpoint: Percentage of Responders Based on Composite Facial Wrinkle Scale Assessment of Crow's Feet Line Severity at Maximum Smile at Day 30. Started Oct 2010; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
Crow's feet
Beyond the preview
Go deeper on NCT01189747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01189747.